BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, June 30, 2026
Breaking News: Science fiction realized: BCI tech is hereBreaking News: Science fiction realized: BCI tech is hereBreaking News: Science fiction realized: BCI tech is here
Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
BioWorld Science, Neurology/psychiatric RSS Feed RSS

Microscopic image of nodes of Ranvier in the myelin sheath
Neurology/Psychiatric

Mature oligodendrocytes play minor role in remyelination

April 20, 2023
By Mar de Miguel
The loss of myelin in the cerebral cortex of multiple sclerosis (MS) patients could be recovered if oligodendrocytes, the cells that myelinate neuronal axons, work at a higher rate than they are destroyed. However, a group of scientists from the University of Munich have shown, in cortical MS mice, that this does not occur. The oligodendrocytes do not contribute to remyelination efficiently.
Read More
Neurology/Psychiatric

Hangzhou Tianji Jishi Biotechnology presents new mitophagy inducers

April 19, 2023
Hangzhou Tianji Jishi Biotechnology Co. Ltd. has divulged naphthylamine compounds reported to be useful as mitophagy inducers.
Read More
Neurology/Psychiatric

Xenon Pharmaceuticals divulges new Nav1.1 activators for epilepsy

April 19, 2023
Xenon Pharmaceuticals Inc. has synthesized pyridinyl derivatives acting as sodium channel protein type 1 subunit α (SCN1A; Nav1.1) activators reported to be useful for the treatment of epilepsy.
Read More
Tau neuron illustration
Neurology/Psychiatric

Enzyme inhibitor reduces tau aggregates in Alzheimer’s models

April 18, 2023
By Mar de Miguel
The inhibition of an enzyme associated with neurodegeneration processes reduced the toxic effect of tau, one of the proteins that damage neurons in Alzheimer’s disease (AD). A group of scientists from the University of Helsinki have shown in vitro and in animal models of AD how inhibition of the prolyl endopeptidase (PREP) enzyme reduced tau protein aggregations.
Read More
Neurology/Psychiatric

Enveric Biosciences Canada patents 5-HT1A or 5-HT2A receptor modulators for the treatment of psychiatric disorders

April 17, 2023
Research at Enveric Biosciences Canada Inc. has led to the development of aminated psilocybin derivatives acting as 5-HT1A or 5-HT2A receptor modulators and reported to be useful for the treatment of psychiatric disorders.
Read More
Neurology/Psychiatric

Shionogi divulges new 5-HT2A and 5-HT2C receptor antagonists and inverse agonists for neurodegeneration

April 17, 2023
Shionogi & Co. Ltd. has synthesized spiroheterocycle derivatives acting as 5-HT2A and 5-HT2C receptor antagonists and/or inverse agonists reported to be useful for the treatment of neurodegeneration.
Read More
Neurology/Psychiatric

Curasen Therapeutics patents new β-adrenoceptor agonists for neurological disorders

April 17, 2023
Curasen Therapeutics Inc. has disclosed compounds acting as β-adrenoceptor agonists reported to be useful for the treatment of neurological disorders.
Read More
3D illustration of a nerve cell
Neurology/Psychiatric

Purdue University discovers novel AC1 inhibitors for chronic pain treatment

April 17, 2023
Chronic inflammatory and neuropathic pain are among the most common chronic conditions, but their treatment options present significant limitations both in efficacy and safety. Researchers from Purdue University presented data on their work aimed to develop adenyl cyclase type 1 (AC1, ADCY1) inhibitors as a new treatment for chronic pain.
Read More
Neurology/Psychiatric

Merck Sharp & Dohme patents nicotinic α7 receptor positive allosteric modulators

April 14, 2023
Merck Sharp & Dohme Corp. have identified nicotinic α7 receptor positive allosteric modulators reported to be useful for the treatment of Alzheimer’s and Parkinson’s diseases, and schizophrenia.
Read More
Neon brain
Substance Use & Poisoning

Discovery and preclinical evaluation of dopamine D4 receptor-selective ligand CAB-01-019

April 14, 2023
Researchers from High Point University recently reported the discovery and preclinical evaluation of a novel class of highly selective dopamine D4 receptor-selective ligands as potential therapeutic candidates for substance use disorders.
Read More
Previous 1 2 … 192 193 194 195 196 197 198 199 200 … 2809 2810 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 29, 2026.
  • Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

    ENCALS 2026: From genetics to advancing strategies against ALS

    BioWorld Science
    Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 30, 2026
  • Handshake with DNA, molecules

    Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement

    BioWorld Science
    Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
  • Digital brain with dollar sign

    Investors bet on transformative BCI tech for neuro disorders

    BioWorld
    An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing